Magnus Expands Access to 5-Day SAINT® Depression Therapy
Magnus Medical Inc. has announced increased availability and access to its SAINT® Depression Therapy as leading health systems adopt the treatment, driven by payer reimbursement and growing patient demand. The company emphasizes the urgency of addressing major depression, a significant public health challenge, afflicting an estimated 47.8 million Americans.
BURLINGAME, Calif.–(BUSINESS WIRE)– #BrainHealth–Magnus Medical Inc., a pioneer in precision neuromodulation for brain health conditions, today announced growing commercial momentum as availability and access to its breakthrough SAINT® Depression Therapy increase, driven by expanding adoption among leading health systems, payer reimbursement, and patient demand. Major depression continues to represent a significant and growing public health burden in the United States, with an estimated 47.8 million Americ